力朴素联合奈达铂化疗对晚期卵巢癌患者血清HE4、CA125、CA 19-9、AFP、CEA及T细胞亚群变化的影响

摘要

Objective:To study the effect of paclitaxel liposome combined with nedaplatin on serum HE4,CA125, CA1 9-9,AFP,CEA and T lymphocyte subsets in patients with advanced ovarian cancer.Methods:A total of 80 patients with advanced ovarian cancer in our hospital from December 2012 to December 201 5 were enrolled in this study.The subjects were divided into control group (n =40)and experiment group (n =40)randomly.The control group were treated with paclitaxel and cisplatin,the experiment group were treated with paclitaxel liposome combined with nedaplatin.21 days for a period of treatment and the two groups were treated for 3 periods.The serum HE4,CA125,CA1 9-9,AFP,CEA levels and peripheral blood CD3 + ,CD4 + ,CD8 + and NK cells of the two groups before and after treatment were compared.Results:There were no significantly differences of the serum HE4,CA125,CA1 9-9,AFP,CEA level and peripheral blood CD3 + ,CD4 + ,CD8 + and NK cells of the two groups before treatment (P >0.05).The serum HE4,CA125,CA1 9-9,AFP and CEA level of the two groups after treatment were significantly lower than before treatment (P <0.05 ),and that of experiment were significantly lower than control group (P <0.05).The peripheral blood CD3 + ,CD4 + ,CD8 + and NK cells of the two groups after treat-ment were significantly lower than before treatment (P <0.05),and that of experiment were significantly higher than control group (P <0.05).Conclusions:Paclitaxel liposome combined with nedaplatin can significantly reduce the serum HE4,CA125, CA1 9-9,AFP and CEA levels,improve peripheral blood CD3 + ,CD4 + ,CD8 + and NK levels of patients with advanced ovarian cancer,and it was worthy clinical application.%目的：：探讨力朴素联合奈达铂化疗对晚期卵巢癌患者血清人附睾分泌蛋白4(human epididymal protein 4,HE4)、糖类抗原125(cancer antigen 125,CA125)、糖类抗原19-9(cancer antigen 19-9,CA19-9)、甲胎蛋白(α-fetoprotein,AFP)、癌胚抗原(carcinoembryonic antigen,CEA)及 T 细胞亚群变化的影响.方法：选择2012年12月~2015年12月在江阴市人民医院确诊的80例晚期卵巢癌患者,随机分为实验组(n ＝40)和对照组(n ＝40).对照组患者给予 TC 化疗方案(紫杉醇＋顺铂),实验组患者给予力朴素联合奈达铂化疗方案,21天为1个疗程,两组患者均给予治疗3个疗程.检测并比较两组患者化疗前后血清 HE4、CA125、CA19-9、AFP、CEA 水平以及外周血 CD3＋、CD4＋、CD8＋及自然杀伤(NK)细胞所占的比值.结果：治疗前,两组患者血清 HE4、CA125、CA19-9、AFP 及 CEA 水平比较差异无统计学意义(P ＞0．05)；治疗后,两组患者血清 HE4、CA125、CA19-9、AFP 及 CEA 水平均明显低于治疗前,同时实验组患者上述各肿瘤标志物水平均明显低于对照组,差异具有统计学意义(P ＜0．05).治疗前,两组患者外周血 CD3＋、CD4＋、CD8＋及 NK 细胞所占比值比较差异无统计学意义(P ＞0．05)；治疗后,两组患者外周血 CD3＋、CD4＋、CD8＋及 NK 细胞所占比值均明显低于治疗前,同时实验组患者各免疫功能指标均明显高于对照组,差异具有统计学意义(P ＜0．05).结论：力朴素联合奈达铂化疗能明显降低晚期卵巢癌患者血清 HE4、CA125、CA19-9、AFP 及 CEA 水平,提高 T 淋巴细胞亚群水平,改善患者机体免疫功能,值得在临床上推广应用.